GRCL — Gracell Biotechnologies Share News
0.000.00%
Last trade - 00:00- $972.69m
- $750.11m
Brief: Gracell Biotechnologies Announces Multiple Advancements Of Truucar Allogeneic Car-T Platform
Brief: Gracell Biotechnologies Doses First Patients In First-In-Human Clinical Trial Evaluating Gc012f In B-Cell Non-Hodgkin's Lymphoma
Brief: Gracell Biotechnologies Inc Says Newly Established Research Facility, Innovation Center, Is Scheduled To Open In San Diego, California, During Q1 Of 2022
Brief: Gracell Biotechnologies Selected For Addition To Nasdaq Biotechnology Index
U.S. STOCKS ON THE MOVE-Apple, Zoom, Abercrombie, Walt Disney
NASDAQ RESUMED AT 09:51 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:38 AM
U.S. STOCKS ON THE MOVE-Apple, Tesla, GoDaddy, Franchise Group
Gracell Biotech jumps as cancer product receives FDA's orphan drug tag
Brief: Gracell Biotechnologies Granted FDA Orphan Drug Designation For Experimental Multiple Myeloma Therapy
Brief: Gracell Biotechnologies Reports Third Quarter 2021 Financial Results
Gracell Biotechnologies Inc reports results for the quarter ended in June - Earnings Summary
Brief: Gracell Biotechnologies Reports Second Quarter 2021 Unaudited Financial Results
Brief: Gracell Biotechnologies Signs Exclusive License Agreement With Futuregen Biopharm
NASDAQ RESUMED AT 01:12 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:07 PM
Brief: Gracell Biotechnologies To Present Updated Results Of Therapy For Relapsed/Refractory Multiple Myeloma At ASCO
Gracell Biotechnologies Inc reports results for the quarter ended in March - Earnings Summary
Brief: Gracell Biotechnologies Reports Qtrly Loss Per Share $0.05